Literature DB >> 15163435

Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.

Michael Ritsner1, Rachel Maayan, Anatoly Gibel, Rael D Strous, Ilan Modai, Abraham Weizman.   

Abstract

Dehydroepiandrosterone (DHEA) and its sulfate derivative DHEA-S are neurosteroids, produced in the brain, and neuroactive steroids, produced in the adrenals and affecting the brain. We compared the ratios of serum cortisol/DHEA or DHEA-S in schizophrenia patients with normal subjects, and determined the correlation of these ratios with psychopathology and distress. Early morning plasma concentrations of DHEA, DHEA-S, and cortisol were determined by radioimmunassay in 40 medicated schizophrenia inpatients, and 15 healthy subjects with similar age and sex distribution. Subjects were assessed for psychopathology using the Positive and Negative Syndrome Scale (PANSS) and the Montgomery and Asberg Depression Rating Scale (MADRS), anxiety, anger, emotional and somatic distress levels. Schizophrenia inpatients demonstrated significantly higher levels of state and trait anxiety, anger expression index, emotional and somatic self-reported distress scores. Cortisol/DHEA and cortisol/DHEA-S ratios were significantly higher in schizophrenia patients than in healthy comparison subjects. Both ratios correlated positively with age and duration of illness; cortisol/DHEA-S ratio also showed positive association with age of illness onset. When age, illness duration and age of onset were controlled, cortisol/DHEA-S ratio significantly correlated with severity of depression (MADRS, r=0.33, p=0.048), state and trait anxiety (r=0.43, p=0.008 and r=0.40, p=0.014, respectively), trait anger (r=0.41, p=0.012), angry temperament (r=0.46, p=0.004), anger expression index (r=0.36, p=0.033), and hostility (r=0.42, p=0.010). No significant association was found between these ratios and severity of psychopathology, and type or dosage of antipsychotic agents. Thus, elevated cortisol/DHEA and/or cortisol/DHEA-S ratios in schizophrenia patients are positively associated with higher scores for anxiety and anger, depression and hostility, age and age of onset/duration of illness, but are independent of severity of psychopathology (PANSS) and antipsychotic treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163435     DOI: 10.1016/j.euroneuro.2003.09.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  28 in total

Review 1.  A new look at the neural diathesis--stress model of schizophrenia: the primacy of social-evaluative and uncontrollable situations.

Authors:  Simon R Jones; Charles Fernyhough
Journal:  Schizophr Bull       Date:  2006-11-14       Impact factor: 9.306

2.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

3.  Cortisol Reactivity to Stress and Its Association With White Matter Integrity in Adults With Schizophrenia.

Authors:  Katie L Nugent; Joshua Chiappelli; Hemalatha Sampath; Laura M Rowland; Kavita Thangavelu; Beshaun Davis; Xiaoming Du; Florian Muellerklein; Stacey Daughters; Peter Kochunov; L Elliot Hong
Journal:  Psychosom Med       Date:  2015-09       Impact factor: 4.312

4.  Diurnal patterns of salivary cortisol and DHEA using a novel collection device: electronic monitoring confirms accurate recording of collection time using this device.

Authors:  Mark L Laudenslager; Jacqueline Calderone; Sam Philips; Crystal Natvig; Nichole E Carlson
Journal:  Psychoneuroendocrinology       Date:  2013-03-13       Impact factor: 4.905

5.  Developmental changes in the endocrine stress response in orangutans (Pongo pygmaeus).

Authors:  Rafaela S C Takeshita; Renata S Mendonça; Fred B Bercovitch; Michael A Huffman
Journal:  J Comp Physiol B       Date:  2019-09-23       Impact factor: 2.200

6.  Day-to-day differences in cortisol levels and molar cortisol-to-DHEA ratios among working individuals.

Authors:  Min-Soo Kim; Young-Jin Lee; Ryun-Sup Ahn
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

7.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

8.  A principal component network analysis of prefrontal-limbic functional magnetic resonance imaging time series in schizophrenia patients and healthy controls.

Authors:  Anca R Rădulescu; Lilianne R Mujica-Parodi
Journal:  Psychiatry Res       Date:  2009-11-02       Impact factor: 3.222

Review 9.  Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Authors:  Michael S Ritsner
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

10.  No evidence of an association between A218C polymorphism of the tryptophan hydroxylase 1 gene and aggression in schizophrenia in a Korean population.

Authors:  Youl-Ri Kim; Joo Young Lee; Sung Kil Min
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.